menu

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

Program Information
Recommended
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
RestartResume
    The FDA found no significant increase in risk of serious asthma outcomes combining long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS)
    • Overview

      The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. 

      A link to the full communication detailing information for health care professionals and the Data Summary can be found at www.fda.gov/DrugSafetyCommunications.

      Released 12/20/2017

    Facebook Comments

    LIVE ON REACHMD RADIOBack to live radio

    Loading...

    Programs 11/17/19

      Get a Dose of ReachMD in Your Inbox
      and Practice Smarter Medicine

      Stay current with the best in medical education.